AstraZeneca builds into China; Eli Lilly hit with 483; GSK’s new collaboration
Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
AstraZeneca and Taizhou National Medical High-tech Development Zone have partnered to expand the Big Pharma’s presence in China, AstraZeneca confirmed to Endpoints News. The company will be investing 190 million yuan ($26.8 million) to build a new production line for metformin hydrochloride and the diabetes therapy Dapagliflozin, as first reported by China Daily.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.